China Post-marketing Surveillance (PMS) Study of Aldurazyme®

Mucopolysaccharidosis I Clinical Trial

Official title:

A Phase 4, Single-arm, Open-label Safety and Efficacy Study of Aldurazyme® (Laronidase) as Enzyme Replacement Therapy in Participants With Mucopolysaccharidosis I (MPS I) in China

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05134571
• Other study ID #: LPS16578
• Secondary ID: U1111-1260-3947
• Status: Completed
• Phase: Phase 4
• Start date: October 28, 2021
• Est. completion date: July 26, 2023

Study information

• Verified date: September 2023
• Source: Sanofi
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a single treatment arm study that is open-label to be conducted in Chinese participants with MPS I. Trial Objectives are to evaluate the safety and tolerability of Aldurazyme in Chinese MPS I participants, and to evaluate the efficacy of Aldurazyme on the percent change of urinary glycosaminoglycans (uGAGs) from baseline to Week 26. The study will also evaluate the effect on uGAG level and liver volume (hepatomegaly) after 26 weeks, with Aldurazyme treatment in Chinese MPS I participants. Treatment duration will include: 2 weeks of screening, 26 weeks of treatment and 1 week of follow-up period. During the treatment period, weekly visits are designed to accommodate weekly administration of Aldurazyme (laronidase).

Description:

Study duration for each participant will be a total of 29 weeks which will include 2 weeks of screening, 26 weeks of treatment period and 1 week of follow-up period.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 12
• Est. completion date: July 26, 2023
• Est. primary completion date: July 26, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 5 Years and older

Eligibility

Inclusion Criteria:

• Chinese participants have a documented diagnosis of MPS I confirmed by measurable clinical signs and symptoms of MPS I and fibroblast or leukocyte IDUA (iduronidase) activity <10% of normal.
• Participants have to be able to stand independently and walk a minimum of 5 meters in 6 minutes.
• A female participant is eligible to participate if she is not pregnant or

breastfeeding, and at least one of the following conditions applies:

• Is not a woman of childbearing potential (WOCBP).
• OR
• Is a WOCBP and agrees to use an acceptable contraceptive method during the intervention period and at a minimum until 7 days after the last dose of study intervention.
• A WOCBP must have a negative highly sensitive pregnancy test (urine or serum as required by local regulations) within the screening period before the first dose of study intervention.
• If a urine test cannot be confirmed as negative (eg, an ambiguous result), a serum pregnancy test is required. In such cases, the participant must be excluded from participation if the serum pregnancy result is positive.
• Contraceptive/barrier method is not applicable for male participants.

Exclusion Criteria:

• Prior tracheostomy or bone marrow transplantation or hematopoietic stem cell transplantation.
• Have a plan to undergo bone marrow transplantation or hematopoietic stem cell transplantation within half a year after enrollment.
• Received an investigational drug, or device, other than Aldurazyme, within 30 days prior to study enrollment.
• Received an investigational gene therapy. The above information is not intended to contain all considerations relevant to a potential participation in a clinical trial.

Related Conditions & MeSH terms

• Mucopolysaccharidoses
• Mucopolysaccharidosis I

Intervention

Drug:
• Laronidase
Solution for injection; Intravenous

Locations

Country	Name	City	State
China	Investigational Site Number :1560002	Beijing
China	Investigational Site Number :1560003	Beijing
China	Investigational Site Number :1560004	Guangzhou
China	Investigational Site Number :1560006	Hangzhou
China	Investigational Site Number :1560001	Wuhan

Sponsors (1)

Lead Sponsor	Collaborator
Genzyme, a Sanofi Company

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Participants with adverse events (AEs)	Incidence of AEs, serious adverse events (SAEs) and adverse events of special interest (AESIs) including infusion associated reactions (IARs) during the treatment emergent (TE) period	Baseline to Week 27
Primary	The incidence of Potentially clinically significant abnormality (PCSA) analyses for clinical laboratory, vital signs, and ECG parameters during the TE period		Baseline to Week 27
Primary	The percent change of uGAGs		Baseline to Week 26
Secondary	The percent change of uGAGs		Baseline to Week 2, Week 4, Week 8, Week 12 and Week 20
Secondary	The absolute change of uGAGs		Baseline to Week 2, Week 4, Week 8, Week 12, Week 20 and Week 26
Secondary	The percent change of liver volume (Abdominal B type ultrasound examination)		Baseline to Week 26